Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methanol extraction residue of bacillus Calmette-Guérin (MER/BCG) is a biologic preparation derived from the Bacillus Calmette-Guérin (BCG) vaccine. BCG itself is an attenuated strain of Mycobacterium bovis used primarily as a vaccine against tuberculosis and as an intravesical immunotherapy for non-muscle invasive bladder cancer. The "methanol extraction residue" refers to a fraction obtained by extracting BCG with methanol, which retains immunostimulatory properties. This product has been investigated for its ability to stimulate the immune system and has been studied in cancer immunotherapy settings, particularly in oncology research contexts[2]. Its mechanism involves activating immune responses that can target tumor cells or infectious agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methanol extraction residue of bacillus Calmette-Guérin.